180 related articles for article (PubMed ID: 38272925)
21. ATRX loss promotes immunosuppressive mechanisms in IDH1 mutant glioma.
Hu C; Wang K; Damon C; Fu Y; Ma T; Kratz L; Lal B; Ying M; Xia S; Cahill DP; Jackson CM; Lim M; Laterra J; Li Y
Neuro Oncol; 2022 Jun; 24(6):888-900. PubMed ID: 34951647
[TBL] [Abstract][Full Text] [Related]
22. Isocitrate dehydrogenase 1 R132H mutation is not detected in angiocentric glioma.
Raghunathan A; Olar A; Vogel H; Parker JR; Coventry SC; Debski R; Albarracin CT; Aldape KD; Cahill DP; Powell SZ; Fuller GN
Ann Diagn Pathol; 2012 Aug; 16(4):255-9. PubMed ID: 22445362
[TBL] [Abstract][Full Text] [Related]
23. Correlation between IDH, ATRX, and TERT promoter mutations in glioma.
Ohba S; Kuwahara K; Yamada S; Abe M; Hirose Y
Brain Tumor Pathol; 2020 Apr; 37(2):33-40. PubMed ID: 32227259
[TBL] [Abstract][Full Text] [Related]
24. ATRX immunohistochemistry can help refine 'not elsewhere classified' categorisation for grade II/III gliomas.
Burford C; Laxton R; Sidhu Z; Aizpurua M; King A; Bodi I; Ashkan K; Al-Sarraj S
Br J Neurosurg; 2019 Oct; 33(5):536-540. PubMed ID: 31018710
[No Abstract] [Full Text] [Related]
25. Morphologically, genetically and spatially mixed astrocytoma and oligodendroglioma; chronological acquisition of 1p/19q codeletion and CDKN2A deletion: a case report.
Takami H; Mukasa A; Takayanagi S; Koike T; Matsuura R; Ikemura M; Ushiku T; Yoshikawa G; Shibahara J; Tanaka S; Saito N
Brain Tumor Pathol; 2023 Jan; 40(1):26-34. PubMed ID: 36572828
[TBL] [Abstract][Full Text] [Related]
26. Adaptive Evolution of the GDH2 Allosteric Domain Promotes Gliomagenesis by Resolving IDH1
Waitkus MS; Pirozzi CJ; Moure CJ; Diplas BH; Hansen LJ; Carpenter AB; Yang R; Wang Z; Ingram BO; Karoly ED; Mohney RP; Spasojevic I; McLendon RE; Friedman HS; He Y; Bigner DD; Yan H
Cancer Res; 2018 Jan; 78(1):36-50. PubMed ID: 29097607
[TBL] [Abstract][Full Text] [Related]
27. Characteristics of IDH-mutant gliomas with non-canonical IDH mutation.
Poetsch L; Bronnimann C; Loiseau H; Frénel JS; Siegfried A; Seizeur R; Gauchotte G; Cappellen D; Carpentier C; Figarella-Branger D; Eimer S; Meyronet D; Ducray F;
J Neurooncol; 2021 Jan; 151(2):279-286. PubMed ID: 33205355
[TBL] [Abstract][Full Text] [Related]
28. ATRX loss in glioneuronal tumors with neuropil-like islands indicates similarity to diffuse astrocytic tumors.
Kakkar A; Nambirajan A; Kaur K; Kumar A; Mallick S; Suri V; Sarkar C; Kale SS; Garg A; Sharma MC
J Neurooncol; 2016 Oct; 130(1):63-68. PubMed ID: 27469217
[TBL] [Abstract][Full Text] [Related]
29. Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations.
Tesileanu CMS; Vallentgoed WR; Sanson M; Taal W; Clement PM; Wick W; Brandes AA; Baurain JF; Chinot OL; Wheeler H; Gill S; Griffin M; Rogers L; Rudà R; Weller M; McBain C; Reijneveld J; Enting RH; Caparrotti F; Lesimple T; Clenton S; Gijtenbeek A; Lim E; de Vos F; Mulholland PJ; Taphoorn MJB; de Heer I; Hoogstrate Y; de Wit M; Boggiani L; Venneker S; Oosting J; Bovée JVMG; Erridge S; Vogelbaum MA; Nowak AK; Mason WP; Kros JM; Wesseling P; Aldape K; Jenkins RB; Dubbink HJ; Baumert B; Golfinopoulos V; Gorlia T; van den Bent M; French PJ
Acta Neuropathol; 2021 Jun; 141(6):945-957. PubMed ID: 33740099
[TBL] [Abstract][Full Text] [Related]
30. Mutant IDH1 Enhances Temozolomide Sensitivity via Regulation of the ATM/CHK2 Pathway in Glioma.
Lin L; Cai J; Tan Z; Meng X; Li R; Li Y; Jiang C
Cancer Res Treat; 2021 Apr; 53(2):367-377. PubMed ID: 33070553
[TBL] [Abstract][Full Text] [Related]
31. Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA sequencing.
Agarwal S; Sharma MC; Jha P; Pathak P; Suri V; Sarkar C; Chosdol K; Suri A; Kale SS; Mahapatra AK; Jha P
Neuro Oncol; 2013 Jun; 15(6):718-26. PubMed ID: 23486690
[TBL] [Abstract][Full Text] [Related]
32. Biphasic IDH1 phenotype in a diffusely infiltrating glioma: implications for pathogenesis, treatment and prognosis.
Odia Y; Varma H; Tsankova NM
Clin Neuropathol; 2015; 34(5):282-7. PubMed ID: 25907263
[TBL] [Abstract][Full Text] [Related]
33. R132H mutation in IDH1 gene reduces proliferation, cell survival and invasion of human glioma by downregulating Wnt/β-catenin signaling.
Cui D; Ren J; Shi J; Feng L; Wang K; Zeng T; Jin Y; Gao L
Int J Biochem Cell Biol; 2016 Apr; 73():72-81. PubMed ID: 26860959
[TBL] [Abstract][Full Text] [Related]
34. Low-Grade Astrocytoma Mutations in IDH1, P53, and ATRX Cooperate to Block Differentiation of Human Neural Stem Cells via Repression of SOX2.
Modrek AS; Golub D; Khan T; Bready D; Prado J; Bowman C; Deng J; Zhang G; Rocha PP; Raviram R; Lazaris C; Stafford JM; LeRoy G; Kader M; Dhaliwal J; Bayin NS; Frenster JD; Serrano J; Chiriboga L; Baitalmal R; Nanjangud G; Chi AS; Golfinos JG; Wang J; Karajannis MA; Bonneau RA; Reinberg D; Tsirigos A; Zagzag D; Snuderl M; Skok JA; Neubert TA; Placantonakis DG
Cell Rep; 2017 Oct; 21(5):1267-1280. PubMed ID: 29091765
[TBL] [Abstract][Full Text] [Related]
35. Utility of ATRX immunohistochemistry in diagnosis of adult diffuse gliomas.
Ikemura M; Shibahara J; Mukasa A; Takayanagi S; Aihara K; Saito N; Aburatani H; Fukayama M
Histopathology; 2016 Aug; 69(2):260-7. PubMed ID: 26741321
[TBL] [Abstract][Full Text] [Related]
36. IDH1-Mutation in Diffuse Gliomas in Persons Age 55 Years and Over.
Robinson C; Kleinschmidt-DeMasters BK
J Neuropathol Exp Neurol; 2017 Feb; 76(2):151-154. PubMed ID: 28110298
[TBL] [Abstract][Full Text] [Related]
37. Loss of H3K27 trimethylation is frequent in IDH1-R132H but not in non-canonical IDH1/2 mutated and 1p/19q codeleted oligodendroglioma: a Japanese cohort study.
Habiba U; Sugino H; Yordanova R; Ise K; Tanei ZI; Ishida Y; Tanikawa S; Terasaka S; Sato KI; Kamoshima Y; Katoh M; Nagane M; Shibahara J; Tsuda M; Tanaka S
Acta Neuropathol Commun; 2021 May; 9(1):95. PubMed ID: 34020723
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of 2-hydroxyglutarate elicits metabolic reprogramming and mutant IDH1 glioma immunity in mice.
Kadiyala P; Carney SV; Gauss JC; Garcia-Fabiani MB; Haase S; Alghamri MS; Núñez FJ; Liu Y; Yu M; Taher A; Nunez FM; Li D; Edwards MB; Kleer CG; Appelman H; Sun Y; Zhao L; Moon JJ; Schwendeman A; Lowenstein PR; Castro MG
J Clin Invest; 2021 Feb; 131(4):. PubMed ID: 33332283
[TBL] [Abstract][Full Text] [Related]
39. Concomitant 1p/19q co-deletion and IDH1/2, ATRX, and TP53 mutations within a single clone of "dual-genotype" IDH-mutant infiltrating gliomas.
Zepeda-Mendoza CJ; Vaubel RA; Zarei S; Ida CM; Matthews M; Acree S; Raghunathan A; Giannini C; Jenkins RB
Acta Neuropathol; 2020 Jun; 139(6):1105-1107. PubMed ID: 32170402
[No Abstract] [Full Text] [Related]
40. Determining IDH-Mutational Status in Gliomas Using IDH1-R132H Antibody and Polymerase Chain Reaction.
Gondim DD; Gener MA; Curless KL; Cohen-Gadol AA; Hattab EM; Cheng L
Appl Immunohistochem Mol Morphol; 2019; 27(10):722-725. PubMed ID: 30358614
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
